ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity

Jing Wei, Xiangyu Chen, Qiang Li, Jifei Chen, Noman Khan, Bing Wang, Jya‐Wei Cheng, John Gordon, Fang LiOncology 2014 · DOI

Abstract

Cisplatin (cis-diamminedichloroplatinum) is a cornerstone of chemotherapy, yet its clinical utility is often restricted by dose-dependent side effects, particularly nephrotoxicity. ELR-CXC chemokines are known to promote tumor growth, metastasis, and angiogenesis, while also acting as potent proinflammatory agents that can exacerbate renal damage. This study evaluated the therapeutic potential of combining cisplatin with the ELR-CXC chemokine antagonist CXCL8(3-72)K11R/G31P (G31P) in a mouse H22 hepatoma model. Results demonstrated that while high-dose cisplatin (12.5 mg/kg) reduced tumor burden by 52%, co-treatment with G31P (50 µg/kg) significantly enhanced this effect to a 71% reduction. Furthermore, G31P effectively mitigated the nephrotoxic markers (BUN and SCr) associated with high-dose cisplatin, bringing them down to levels observed in low-dose (2 mg/kg) treatments. These findings suggest that ELR-CXC antagonism is a viable strategy to enhance chemotherapeutic efficacy while simultaneously reducing systemic toxicity.

Introduction

Cisplatin remains one of the most effective agents for treating various cancers, but it is a double-edged sword. Its primary limitation is dose-dependent nephrotoxicity, which can lead to acute renal failure. Recent research highlights the role of ELR-CXC chemokines—signaling proteins that recruit neutrophils—in both tumor progression and the inflammatory response to chemotherapy. In cancer, these chemokines promote angiogenesis and help tumors resist treatment. In the kidneys, cisplatin triggers a "chemokine storm" that worsens tissue damage. This study investigates whether blocking these receptors (CXCR1 and CXCR2) using the antagonist G31P can improve oncological outcomes while shielding renal function.

Methods

The researchers utilized a C57BL/6 mouse model injected with H22 hepatoma (liver cancer) cells. Treatment groups included:

  • Control: Saline injections.
  • G31P alone: 50 µg/kg.
  • Low-dose Cisplatin (DDP): 2 mg/kg.
  • High-dose Cisplatin (DDP): 12.5 mg/kg.
  • Co-treatment: High-dose DDP plus G31P.

Renal function was monitored via Blood Urea Nitrogen (BUN) and Serum Creatinine (SCr) levels. Tumor progression was assessed by primary tumor weight and lymph node metastasis. Molecular analysis included qRT-PCR for inflammatory markers (IL-1β, KC, and MIP-2) and Immunohistochemistry (IHC) for VEGF-D expression.

Key Results

Enhanced Tumor Suppression and Systemic Recovery

The most significant finding was the additive effect of G31P and cisplatin. While high-dose cisplatin alone reduced tumor weight from ~1.8g (saline) to ~0.8g, the addition of G31P further suppressed growth to ~0.5g. Beyond tumor size, G31P provided a protective effect on overall health; mice receiving high-dose cisplatin typically experience significant weight loss, but the co-treatment group showed improved body weight recovery compared to cisplatin alone.

Figure 1: Body weight changes over time (A) and final tumor weights (B) across treatment groups.

Mitigation of Metastatic Markers

High-dose cisplatin treatment reduced the expression of VEGF-D, a key protein involved in tumor spread, by approximately 50%. The co-treatment with G31P maintained this suppression and was associated with a near-total elimination of visible metastases in inguinal lymph nodes. IHC analysis confirmed that VEGF expression was significantly lower in the high-dose and co-treatment groups compared to saline or low-dose cisplatin controls.

Figure 6: Immunohistochemical analysis (A) and quantification (B) of VEGF expression in tumor tissues.

Renal Protection

High-dose cisplatin caused a sharp spike in BUN levels (~10 mmol/L). In the co-treatment group, G31P blunted this inflammatory response, maintaining BUN levels at approximately 6 mmol/L, mirroring the safer profile of low-dose cisplatin. This suggests that G31P attenuates the secondary inflammatory wave (specifically KC and MIP-2) triggered by cisplatin injury.

Discussion and Insights

This study demonstrates a rare "decoupling" of toxicity from efficacy. Typically, increasing the potency of a chemotherapeutic regimen increases its side effects. Here, G31P allowed for the high-dose efficacy of cisplatin while maintaining the safety profile of a low-dose treatment. The researchers hypothesize that G31P not only reduces inflammation but may also activate anti-apoptotic pathways in kidney cells, though further research is required to confirm these molecular mechanisms.

Conclusion

The combination of ELR-CXC chemokine antagonism and cisplatin represents a promising therapeutic strategy. By enhancing tumor suppression and protecting the kidneys, G31P could allow clinicians to utilize more aggressive chemotherapy doses with fewer debilitating side effects. Future work should focus on validating these results across different cancer types and optimizing clinical dosing schedules.

Summary updated

Abstract

Cisplatin (cis-diamminedichloroplatinum) is one of the most commonly used agents for the chemotherapy of various types of cancers, but its use is limited by its dose-dependent side-effects (e.g., nephrotoxicity). The ELR-CXC chemokines are potent tumor growth, metastatic and angiogenic factors and can foster tumor resistance to chemotherapeutic agents. They are also potent proinflammatory agents. The aim of the present study was to evaluate the added effects of combining cisplatin chemotherapy with ELR-CXC chemokine antagonism in a mouse H22 hepatoma cancer cell model. The mice were injected with tumor cells and were then treated with cisplatin (12.5 or 2 mg/kg doses), either alone or together with the chemokine antagonist CXCL8(3-72)K11R/G31P (G31P) (50 µg/kg). At varying time-points renal function was examined using blood urea nitrogen (BUN) and serum creatinine (SCr) as read-outs for the toxic effects of cisplatin, while tumor growth and metastasis were assessed as endpoints. High-dose cisplatin therapy reduced the tumor burden by 52%, while co-delivery of G31P further augmented the tumor growth-suppressive effects of this dose of cisplatin to 71%; G31P by itself and low-dose cisplatin reduced the tumor burden by 19 and 39%, respectively. G31P also reduced the nephrotoxic effects of high-dose cisplatin to the effects observed in the low-dose cisplatin-treated animals. These data confirm the beneficial effects of combined cisplatin chemotherapy and ELR-CXC chemokine anatagonism in the context of both tumor progression and adverse side-effects.
BibTeX
@inproceedings{wei2014elr,
  author = {Jing Wei and Xiangyu Chen and Qiang Li and Jifei Chen and Noman Khan and Bing Wang and Jya‐Wei Cheng and John Gordon and Fang Li},
  title = {{ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity}},
  booktitle = {Oncology},
  year = {2014},
  doi = {10.3892/or.2014.2996},
}
Figure